S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|MWV’s MEMS System chosen for trials of HIV-prevention medication in Africa and India (2014/12/1)|
|FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy (2014/12/8)|
|IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients (2015/1/5)|
|Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH™ Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia (2015/1/29)|
|Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer (2015/2/27)|
|Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting (2014/12/2)|
|AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting (2014/12/7)|
|Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases (2014/12/7)|
|Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL) Patients (2014/12/5)|
|FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera (2014/12/4)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
Click above to view more mutual fund data and stats for clin - Cleopatra International Group Inc.